世界の頭頸部がん治療薬/治療剤市場2020年:企業別、地域別、種類・用途別

【英語タイトル】Global Head and Neck Cancer Drugs/Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20SP03067)・商品コード:GIR20SP03067
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年9月18日(※2024年版があります。お問い合わせください)
・ページ数:102
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、頭頸部がん治療薬/治療剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。頭頸部がん治療薬/治療剤の種類別市場規模(PD阻害剤、微小管阻害剤、EGFR阻害剤)、用途別市場規模(手術、放射線療法、化学療法、免疫療法)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Sanofi、DFG、Actavis、Eli Lilly、Teva Pharmaceutical、Amgen、Jiangsu Hengrui、Dr. Reddy’s Laboratories、BioXpress
・地域別グローバル市場分析 2015年-2020年
・頭頸部がん治療薬/治療剤の北米市場(アメリカ、カナダ、メキシコ)
・頭頸部がん治療薬/治療剤のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・頭頸部がん治療薬/治療剤のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・頭頸部がん治療薬/治療剤の南米市場(ブラジル、アルゼンチン)
・頭頸部がん治療薬/治療剤の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:PD阻害剤、微小管阻害剤、EGFR阻害剤
・用途別分析:手術、放射線療法、化学療法、免疫療法
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Head and Neck Cancer Drugs/Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1466.9 million by 2025, from USD 1255.8 million in 2019.

The Head and Neck Cancer Drugs/Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Head and Neck Cancer Drugs/Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Head and Neck Cancer Drugs/Therapeutics market has been segmented into:
PD Inhibitors
Microtubule Inhibitors
EGFR Inhibitors

By Application, Head and Neck Cancer Drugs/Therapeutics has been segmented into:
Surgery
Radiation therapy
Chemotherapy
Immunotherapy

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Head and Neck Cancer Drugs/Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Head and Neck Cancer Drugs/Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Head and Neck Cancer Drugs/Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Head and Neck Cancer Drugs/Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Head and Neck Cancer Drugs/Therapeutics Market Share Analysis
Head and Neck Cancer Drugs/Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Head and Neck Cancer Drugs/Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Head and Neck Cancer Drugs/Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Head and Neck Cancer Drugs/Therapeutics are:
Sanofi
DFG
Actavis
Eli Lilly
Teva Pharmaceutical
Amgen
Jiangsu Hengrui
Dr. Reddy’s Laboratories
BioXpress

【レポートの目次】

Table of Contents

1 Head and Neck Cancer Drugs/Therapeutics Market Overview
1.1 Product Overview and Scope of Head and Neck Cancer Drugs/Therapeutics
1.2 Classification of Head and Neck Cancer Drugs/Therapeutics by Type
1.2.1 Global Head and Neck Cancer Drugs/Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Type in 2019
1.2.3 PD Inhibitors
1.2.4 Microtubule Inhibitors
1.2.5 EGFR Inhibitors
1.3 Global Head and Neck Cancer Drugs/Therapeutics Market by Application
1.3.1 Overview: Global Head and Neck Cancer Drugs/Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Surgery
1.3.3 Radiation therapy
1.3.4 Chemotherapy
1.3.5 Immunotherapy
1.4 Global Head and Neck Cancer Drugs/Therapeutics Market by Regions
1.4.1 Global Head and Neck Cancer Drugs/Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Head and Neck Cancer Drugs/Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Head and Neck Cancer Drugs/Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Head and Neck Cancer Drugs/Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Head and Neck Cancer Drugs/Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Head and Neck Cancer Drugs/Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Head and Neck Cancer Drugs/Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi SWOT Analysis
2.1.4 Sanofi Product and Services
2.1.5 Sanofi Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 DFG
2.2.1 DFG Details
2.2.2 DFG Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 DFG SWOT Analysis
2.2.4 DFG Product and Services
2.2.5 DFG Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Actavis SWOT Analysis
2.3.4 Actavis Product and Services
2.3.5 Actavis Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Teva Pharmaceutical
2.5.1 Teva Pharmaceutical Details
2.5.2 Teva Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Teva Pharmaceutical SWOT Analysis
2.5.4 Teva Pharmaceutical Product and Services
2.5.5 Teva Pharmaceutical Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Amgen SWOT Analysis
2.6.4 Amgen Product and Services
2.6.5 Amgen Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Jiangsu Hengrui
2.7.1 Jiangsu Hengrui Details
2.7.2 Jiangsu Hengrui Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Jiangsu Hengrui SWOT Analysis
2.7.4 Jiangsu Hengrui Product and Services
2.7.5 Jiangsu Hengrui Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Dr. Reddy’s Laboratories
2.8.1 Dr. Reddy’s Laboratories Details
2.8.2 Dr. Reddy’s Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Dr. Reddy’s Laboratories SWOT Analysis
2.8.4 Dr. Reddy’s Laboratories Product and Services
2.8.5 Dr. Reddy’s Laboratories Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 BioXpress
2.9.1 BioXpress Details
2.9.2 BioXpress Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 BioXpress SWOT Analysis
2.9.4 BioXpress Product and Services
2.9.5 BioXpress Head and Neck Cancer Drugs/Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Head and Neck Cancer Drugs/Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Head and Neck Cancer Drugs/Therapeutics Players Market Share
3.2.2 Top 10 Head and Neck Cancer Drugs/Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Head and Neck Cancer Drugs/Therapeutics Revenue and Market Share by Regions
4.2 North America Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries
5.1 North America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
5.2 USA Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Head and Neck Cancer Drugs/Therapeutics Revenue by Countries
6.1 Europe Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue by Countries
7.1 Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
7.2 China Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries
8.1 South America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Head and Neck Cancer Drugs/Therapeutics by Countries
9.1 Middle East & Africa Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Head and Neck Cancer Drugs/Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Head and Neck Cancer Drugs/Therapeutics Market Forecast by Type (2019-2024)
10.3 PD Inhibitors Revenue Growth Rate (2015-2025)
10.4 Microtubule Inhibitors Revenue Growth Rate (2015-2025)
10.5 EGFR Inhibitors Revenue Growth Rate (2015-2025)
11 Global Head and Neck Cancer Drugs/Therapeutics Market Segment by Application
11.1 Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Head and Neck Cancer Drugs/Therapeutics Market Forecast by Application (2019-2024)
11.3 Surgery Revenue Growth (2015-2020)
11.4 Radiation therapy Revenue Growth (2015-2020)
11.5 Chemotherapy Revenue Growth (2015-2020)
11.6 Immunotherapy Revenue Growth (2015-2020)
12 Global Head and Neck Cancer Drugs/Therapeutics Market Size Forecast (2021-2025)
12.1 Global Head and Neck Cancer Drugs/Therapeutics Market Size Forecast (2021-2025)
12.2 Global Head and Neck Cancer Drugs/Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Head and Neck Cancer Drugs/Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Sanofi Corporate Information, Location and Competitors
Table 6. Sanofi Head and Neck Cancer Drugs/Therapeutics Major Business
Table 7. Sanofi Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Sanofi SWOT Analysis
Table 9. Sanofi Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 10. Sanofi Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. DFG Corporate Information, Location and Competitors
Table 12. DFG Head and Neck Cancer Drugs/Therapeutics Major Business
Table 13. DFG Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. DFG SWOT Analysis
Table 15. DFG Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 16. DFG Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Actavis Corporate Information, Location and Competitors
Table 18. Actavis Head and Neck Cancer Drugs/Therapeutics Major Business
Table 19. Actavis Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Actavis SWOT Analysis
Table 21. Actavis Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 22. Actavis Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Eli Lilly Corporate Information, Location and Competitors
Table 24. Eli Lilly Head and Neck Cancer Drugs/Therapeutics Major Business
Table 25. Eli Lilly Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Eli Lilly SWOT Analysis
Table 27. Eli Lilly Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 28. Eli Lilly Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Teva Pharmaceutical Corporate Information, Location and Competitors
Table 30. Teva Pharmaceutical Head and Neck Cancer Drugs/Therapeutics Major Business
Table 31. Teva Pharmaceutical Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Teva Pharmaceutical SWOT Analysis
Table 33. Teva Pharmaceutical Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 34. Teva Pharmaceutical Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Amgen Corporate Information, Location and Competitors
Table 36. Amgen Head and Neck Cancer Drugs/Therapeutics Major Business
Table 37. Amgen Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Amgen SWOT Analysis
Table 39. Amgen Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 40. Amgen Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Jiangsu Hengrui Corporate Information, Location and Competitors
Table 42. Jiangsu Hengrui Head and Neck Cancer Drugs/Therapeutics Major Business
Table 43. Jiangsu Hengrui Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Jiangsu Hengrui SWOT Analysis
Table 45. Jiangsu Hengrui Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 46. Jiangsu Hengrui Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Dr. Reddy’s Laboratories Corporate Information, Location and Competitors
Table 48. Dr. Reddy’s Laboratories Head and Neck Cancer Drugs/Therapeutics Major Business
Table 49. Dr. Reddy’s Laboratories Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Dr. Reddy’s Laboratories SWOT Analysis
Table 51. Dr. Reddy’s Laboratories Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 52. Dr. Reddy’s Laboratories Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. BioXpress Corporate Information, Location and Competitors
Table 54. BioXpress Head and Neck Cancer Drugs/Therapeutics Major Business
Table 55. BioXpress Head and Neck Cancer Drugs/Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. BioXpress SWOT Analysis
Table 57. BioXpress Head and Neck Cancer Drugs/Therapeutics Product and Solutions
Table 58. BioXpress Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 60. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Players (2015-2020)
Table 61. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Regions (2015-2020)
Table 63. North America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
Table 64. North America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Table 65. Europe Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Head and Neck Cancer Drugs/Therapeutics Revenue by Countries (2015-2020)
Table 68. South America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 72. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Type (2015-2020)
Table 73. Global Head and Neck Cancer Drugs/Therapeutics Revenue Forecast by Type (2021-2025)
Table 74. Global Head and Neck Cancer Drugs/Therapeutics Revenue by Application (2015-2020)
Table 75. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Application (2015-2020)
Table 76. Global Head and Neck Cancer Drugs/Therapeutics Revenue Forecast by Application (2021-2025)
Table 77. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Head and Neck Cancer Drugs/Therapeutics Picture
Figure 2. Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Type in 2019
Figure 3. PD Inhibitors Picture
Figure 4. Microtubule Inhibitors Picture
Figure 5. EGFR Inhibitors Picture
Figure 6. Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Application in 2019
Figure 7. Surgery Picture
Figure 8. Radiation therapy Picture
Figure 9. Chemotherapy Picture
Figure 10. Immunotherapy Picture
Figure 11. Global Head and Neck Cancer Drugs/Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Head and Neck Cancer Drugs/Therapeutics Revenue Market Share in 2019
Figure 20. Global Top 10 Players Head and Neck Cancer Drugs/Therapeutics Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 24. Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Regions in 2018
Figure 25. North America Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Europe Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. South America Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. North America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 31. North America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries in 2019
Figure 32. USA Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Canada Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. Europe Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries in 2019
Figure 37. Germany Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. UK Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. France Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Russia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Italy Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries in 2019
Figure 44. China Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Japan Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Korea Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. India Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. South America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 50. South America Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries in 2019
Figure 51. Brazil Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. UAE Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Head and Neck Cancer Drugs/Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Type (2015-2020)
Figure 60. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Type in 2019
Figure 61. Global Head and Neck Cancer Drugs/Therapeutics Market Share Forecast by Type (2021-2025)
Figure 62. Global PD Inhibitors Revenue Growth Rate (2015-2020)
Figure 63. Global Microtubule Inhibitors Revenue Growth Rate (2015-2020)
Figure 64. Global EGFR Inhibitors Revenue Growth Rate (2015-2020)
Figure 65. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Application (2015-2020)
Figure 66. Global Head and Neck Cancer Drugs/Therapeutics Revenue Share by Application in 2019
Figure 67. Global Head and Neck Cancer Drugs/Therapeutics Market Share Forecast by Application (2021-2025)
Figure 68. Global Surgery Revenue Growth Rate (2015-2020)
Figure 69. Global Radiation therapy Revenue Growth Rate (2015-2020)
Figure 70. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 71. Global Immunotherapy Revenue Growth Rate (2015-2020)
Figure 72. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Head and Neck Cancer Drugs/Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Head and Neck Cancer Drugs/Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. Europe Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. South America Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Head and Neck Cancer Drugs/Therapeutics Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Sanofi、DFG、Actavis、Eli Lilly、Teva Pharmaceutical、Amgen、Jiangsu Hengrui、Dr. Reddy’s Laboratories、BioXpress

★調査レポート[世界の頭頸部がん治療薬/治療剤市場2020年:企業別、地域別、種類・用途別] (コード:GIR20SP03067)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の頭頸部がん治療薬/治療剤市場2020年:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆